The epithelial to mesenchymal transition is a developmental process allowing epithelial cells to dedifferentiate into cells displaying mesenchymal phenotypes. The pathological role of epithelial to mesenchymal transition has been implicated in invasion and metastasis for numerous carcinomas, yet limited data exist addressing whether mesenchymal transition (MT) occurs in malignant melanoma cells. Our group developed an in-vitro three-dimensional culture system to address MT in melanoma cells upon transforming growth factorb/ tumor necrosis factor-a treatment. Loss of E-cadherin is one of the best indicators of MT in epithelial cells. Not surprisingly, E-cadherin was expressed in only three of 12 (25%) melanoma cell lines and all three mesenchymal proteins, N-cadherin, vimentin, and fibronectin, were expressed by seven (58%) melanoma cell lines. However, after cytokine treatment, two or more mesenchymal proteins were elevated in nine (75%) melanoma cell lines. Data support the transforming growth factor-b production by melanoma cells which may induce/support MT. Evaluation of E-cadherin, N-cadherin, and Snail expression in melanoma tissue samples are consistent with an inverse coupling of E-cadherin and N-cadherin expression, however, there are also examples suggesting a more complex control of their expression. These results indicate that malignant melanoma cell lines are susceptible to MT after cytokine treatment and highlight the importance of understanding the effects of cytokines on melanoma to undergo MT.
Introduction
Epithelial to mesenchymal transition (EMT) is a process whereby the epithelial cells lose epithelial features and acquire properties of mesenchymal cells. EMT is associated with decreased expression of epithelial markers such as E-cadherin, and increased expression of mesenchymal markers such as N-cadherin, vimentin, and fibronectin (reviewed in [1] ). This transition to a more mesenchymal phenotype is also characterized by a loss of cell-cell adhesion, cytoskeletal remodeling, and increased cell motility. EMT is a normal process that occurs during many stages of embryonic development, however, there is growing evidence to suggest that the ability of cancer cells to metastasize is facilitated by a mesenchymal morphology (reviewed in [2] ). The change in adhesion molecule expression causes the cells to detach from epithelium and to gain the ability to migrate to distant sites. The loss of epithelial cell markers such as Ecadherin has been associated with metastatic potential and poor prognosis of several carcinomas [3] [4] [5] . EMT can be induced in vitro in carcinoma cells with transforming growth factor (TGF-b), tumor necrosis factor (TNF-a), or other cytokines [6] [7] [8] . Treating epithelial cancer cells with both TGF-b and TNF-a induces a more complete EMT than either alone ( [9] and Mayo, unpublished data).
Although found embedded within the basal layer of squamous epidermal epithelial cells, melanocytes are not considered epithelial because they do not form a lining. However, their migration from the neural crest ectoderm during embryologic development may be facilitated by a transient mesenchymal phenotype (reviewed in [10, 11] ). Like the epithelial cells, adult melanocytes express E-cadherin which maintains keratinocyte contact and regulation; its loss can contribute to an invasive phenotype [12, 13] . In addition, adult melanocytes are negative for N-cadherin, but melanoma cells can express it. N-cadherin allows coupling to dermal fibroblasts and vascular endothelial cells in the tumor stroma, which is thought to facilitate metastasis [13, 14] . The switch from E-cadherin to N-cadherin expression by the melanoma cells has been observed, and melanoma cells commonly express the mesenchymal protein vimentin, suggesting that a degree of mesenchymal transition (MT) may be constitutive in some melanomas. E-cadherin expression is negatively regulated by the transcription factor Snail [15] . Expression of N-cadherin is increased in metastatic versus nonmetastatic melanoma [16] , further suggesting a possible association of MT and metastatic potential. However, the range and variability in constitutive expression of epithelial and mesenchymal proteins is not known for human melanomas, and it is not known whether melanoma cells undergo MT-like epithelial cells in response to TGF-b and TNF-a.
To assess whether the melanoma cells can undergo transition to a more mesenchymal phenotype upon cytokine treatment, we treated melanoma cell lines with TGF-b and TNF-a in a three-dimensional culture system and evaluated the changes in the expression of Ecadherin, N-cadherin, vimentin, and fibronectin. This system represents a more biologically relevant model than monolayer culture to examine in which the effects of cytokine treatment are seen on melanoma cell lines ( [9] and Mayo, unpublished data). In addition, we evaluated cytokine production by the melanoma cell lines before TGF-b and TNF-a treatment, and evaluated E-cadherin, N-cadherin, and Snail expression in 197 melanoma tissue samples. This study reveals a range of epithelialmesenchymal features among different melanomas, and also suggests that MT may be induced in most human melanoma cell lines.
Methods

Cell lines
Melanoma cell lines VMM1, VMM5A, VMM12, VMM14, VMM15, VMM18, VMM19, VMM39, and VMM1040 were cell lines established from patients with metastatic lesions at the University of Virginia [17] [18] [19] [20] [21] [22] [23] . Research involving human participants was performed with informed consent and approved by the University of Virginia's Institutional Review Board. Melanoma cell line DM93 was obtained from Duke University [24] . Melanoma cell lines SK-MEL-24 and WM115 and a non-small cell lung carcinoma, A549, were obtained from the American Type Culture Collection. Cell lines derived from metastatic melanoma lesions were cultured from tumor-involved lymph nodes (VMM5A, VMM12, VMM14, VMM15, VMM18, VMM19, VMM39, DM93, and SK-MEL-24), a brain metastasis (VMM1), or a recurrent melanoma lesion on the shoulder (VMM1040). Melanoma VMM1040 was a low passage cell line (P6). WM115 was a cell line derived from a primary tumor that produced metastatic lesions [25] . Cell lines are summarized in Table 1 . Melanoma cell lines were grown as adherent cultures in a two-dimensional culture system in RPMI 1640 supplemented with 5% fetal bovine serum (FBS), L-glutamine (2 mmol/l), penicillin (100 units/ml), and streptomycin (100 mg/ml) at 371C in 5% CO 2 before introduction to the three-dimensional culture system. A549 was cultured in Dulbecco's modified Eagle's medium (high glucose) supplemented with 10% FBS, penicillin (100 units/ml), and streptomycin (100 mg/ml) at 371C in 5% CO 2 in a two-dimensional culture system before three-dimensional culture.
Reagents
TGF-b1 and TNF-a were purchased from Sigma and used at 2 and 10 ng/ml, respectively to induce EMT ( [9] and Mayo, unpublished data). Poly (2-hydroxyethyl methacrylate) (Poly-HEMA, Sigma) was used to coat Petri dishes to inhibit cell adhesion to the dish surface. Poly-HEMA (10 mg/ml in EtOH) was dispensed into Petri dishes and allowed to air dry overnight before using for three-dimensional cell culture.
Three-dimensional cell culture and transition of cells
Melanoma or lung carcinoma cell lines growing in twodimensional culture flasks were trypsinized, counted, and resuspended at 800 000 cells/ml in either RPMI 1640 supplemented with 5% FBS, L-glutamine (2 mmol/l), penicillin (100 units/ml), and streptomycin (100 mg/ml) (melanoma) or Dulbecco's modified Eagle's medium (high glucose) supplemented with 10% FBS, penicillin (100 units/ml), and streptomycin (100 ug/ml) (lung carcinoma). On the lid of a tissue culture plate, 20 000 cells were plated in a single drop and inverted. The cells were incubated at 371C in 5% CO 2 for 48-72 h. After 48-72 h, the cell aggregates that formed in the inverted drop were transferred to a Poly-HEMA-treated Petri dish in either RPMI 1640 supplemented with 1% FBS, Lglutamine (2 mmol/l), penicillin (100 units/ml), and streptomycin (100 mg/ml) (melanoma) or Dulbecco's modified Eagle's medium (high glucose) supplemented with 2% FBS, penicillin (100 units/ml), and streptomycin (100 mg/ml) (lung carcinoma). Cells were either left untreated or were treated with TGF-b and TNF-a. After a 48 h incubation at 371C in 5% CO 2 , additional TGF-b and TNF-a were added to the treated cells. Cells were incubated at 371C in 5% CO 2 for an additional 48 h. After 4 days with TGF-b and TNF-a, cells were harvested for analysis. Select cell lines were analyzed by flow cytometry DM93  TIN  SK-MEL-24  TIN  VMM5A  TIN  VMM12  TIN  VMM14  TIN  VMM15  TIN  VMM18  TIN  VMM19  TIN  VMM39  TIN  VMM1 Brain metastasis TIN, tumor-involved nodes.
using 7-amino-actinomycin D (Calbiochem, San Diego, California, USA) to determine cell viability.
SDS-PAGE and western blot analysis
After 4 days of three-dimensional culture, untreated and TGF-b/TNF-a-treated cells were harvested for western blot analysis. In brief, the cells were rinsed with PBS and lysed in RIPA lysis buffer (ice-cold 150 mmol/l NaCl, 1% NP-40, 12 mmol/l deoxycholate, 0.1% SDS, 50 mmol/l Tris, pH 7.6, 4 mmol/l EDTA, 0.01% glycerol, and Roche complete mini protease inhibitor cocktail). The lysate was centrifuged for 5 min at 10 000 g at 41C and the supernatant was stored at -801C for further analysis. Protein yield was determined by BCA protein assay according to the manufacturer's protocol (Thermo Scientific). The protein lysate was resuspended in SDScontaining sample buffer and heated for 10 min at 701C. The lysate (20 mg/lane) was electrophoresed using 4-12% gradient Bis-Tris SDS gels (Invitrogen) and transferred to a PVDF membrane (Immobilon-P, Millipore, USA). Membranes were blocked in 3% non-fat dry milk, 50 mmol/l Tris-Cl, pH 7.5, 0.9% NaCl, and 0.1% Tween-20 at room temperature for 1 h. Membranes were probed with antibodies at 41C overnight or at room temperature for 1 h. Proteins were detected with either SuperSignal West Pico (Thermo Scientific) or Immobilon Western (Millipore) Chemiluminescent HRP substrate and exposed to Kodak BioMax film. Semiquantitative analysis was performed based on a band intensity grading scale of 0-4 ( Fig. 1 ) and the following film exposure times: Ecadherin and vimentin 2 min exposure to film, Ncadherin 5-15 s exposure to film, fibronectin 15 s exposure or 2 min exposure with diluted chemiluminescent reagent. Equal loading of protein was assessed based on GAPDH protein expression. Protein expression that appeared to be equal in the untreated and TGF-b/TNF-a treated samples were reanalyzed by western blot at 10, 5, and/or 2.5 mg/lane to confirm western blot intensity was in the linear range.
Western analysis antibodies
Anti-glyceraldehyde-3-phosphate dehydrogenase antibody was purchased from Chemicon International (Temecula, CA, USA) and used at 1 : 5000. Anti-E-cadherin antibody (clone 34/E-cadherin) was purchased from BD Biosciences (San Jose, CA, USA)and used at 1 : 700 or 1 : 250. Anti-N-cadherin antibody (clone 32/N-cadherin) was purchased from BD Biosciences and used at 1 : 700. Anti-fibronectin antibody (clone 10/fibronectin) was purchased from BD Biosciences and used at 1 : 700. Anti-vimentin antibody (clone 2Q1123) was purchased from SantaCruz Biotechnology (Santa Cruz, CA, USA) and used at 1 : 1000. Secondary antibody, ECL anti-mouse IgG, horseradish peroxidase-linked whole antibody from sheep was purchased from GE Healthcare Biosciences (Piscataway, NJ, USA) and used at 1 : 5000.
Melanoma tissue microarray
Formalin-fixed, paraffin embedded tumor blocks were retrieved from the archives of the Department of Pathology, University of Virginia Health System. The melanoma tissue microarray (TMA) blocks were constructed by obtaining 1.0 mm tissue cores from tumor areas of each block and transferring into a recipient paraffin block. Nine TMA blocks were created with quadruplicate or triplicate cores from 197 surgical pathology specimens represented by 695 melanoma cores. Nine specimens were from primary melanoma and 188 specimens were from metastatic melanoma. Multiple 4 mm sections were cut and consecutive sections were used for H&E and immunohistochemical staining.
Immunohistochemistry
After reviewing the hemotoxylin and eosin stained TMA slides, immunohistochemical stains were performed on the TMA tissue sections using antibodies against human E-cadherin ( after they were transferred to a Poly-HEMA treated Petri dish (before the addition of cytokines to induce MT). Supernatants were centrifuged and aliquots were removed and stored at -801C until analyzed. Quantitative cytokine production was measured using a chemiluminescent ELISA (TNF-a) or a colorimetric ELISA (TGF-b1) according to manufacturer's instructions (R&D Systems). A standard curve was generated using the supplied reagents. TGF-b1 samples were activated to detect the free and latent TGF-b1. Background levels of TNF-a or TGF-b1 from the serum containing media were subtracted from the samples. The concentration of cytokine produced by the cells in three-dimensional culture was calculated using the average value from duplicate samples.
Statistical methods
Relative intensity on western blot analysis was determined for E-cadherin, N-cadherin, vimentin and fibronectin protein expression at baseline as described earlier.
A linear regression analysis was performed with Ecadherin versus each of the three mesenchymal proteins and N-cadherin versus fibronectin and vimentin. For each graph, a linear regression analysis was performed and r 2 values were calculated using GraphPad Prism 4 software.
Results
Baseline epithelial/mesenchymal protein expression in melanoma cell lines
We evaluated the baseline expression of epithelial and mesenchymal proteins in 12 human melanoma cell lines (11 derived from metastatic melanoma and one from primary melanoma) (Table 1 ) and compared them with A549, a non-small cell lung carcinoma that undergoes EMT upon cytokine treatment ( [9] and Mayo, unpublished data). Cells were cultured in a three-dimensional culture system, which is more physiologically relevant than monolayer culture and allows cells to organize into structures that resemble their in-vivo architecture. Cells were harvested, and evaluated for protein expression by western blot, with semiquantitative measures.
As expected, E-cadherin was detected in the lung cancer cell line A549 (X) at a relative expression level of 2, but was expressed in only three of 12 melanoma cell lines (A-C, Fig. 1a ) at relative expression levels of 1.5-2.5. No correlations were observed between levels of E-cadherin and any of the three mesenchymal proteins N-cadherin, fibronectin, or vimentin ( Fig. 1b-d ) (r 2 = 0.06, 0.04, and 0.24, respectively).
N-cadherin was undetectable in two lines (VMM5A and VMM1040), low (intensity < 2) in three lines, moderate in three lines (2 Z intensity < 3), and high (intensity Z 3) in four lines ( Fig. 1e and f) . Fibronectin was undetectable in two lines, low in three, moderate in three, and high in four (Fig. 1e ). Vimentin was undetectable in one line (DM93), moderate in five lines, and high in six lines (Fig. 1f ). Seven of the 12 melanoma cell lines express all three mesenchymal proteins at baseline, whereas the other five melanoma cell lines express two of the three mesenchymal proteins at baseline. No correlations were observed between the expression of mesenchymal proteins N-cadherin and fibronectin or vimentin ( Fig. 1e and f) (r 2 = 0.02 and 0.03, respectively).
Mesenchymal transition associated protein changes induced by TGF/TNF treatment
To evaluate if TGF-b and TNF-a could induce MT of melanoma cell lines, we treated 12 melanoma cell lines with TGF-b and TNF-a for 4 days in a three-dimensional culture system. This treatment induced decreases in E-cadherin and increases in N-cadherin, fibronectin, and vimentin, both for the lung carcinoma A549 (positive control X, Fig. 2a ) and for one melanoma cell line DM93 (A, Fig. 2a ). In contrast, for the melanoma cell line VMM18 (B), the cytokines induced decreases in Ecadherin and vimentin and increases in N-cadherin and fibronectin ( Fig. 2a ). Repeat testing for A549, VMM18, and others were performed several times with consistent findings. Repeat testing for VMM18 is shown (Fig. 2b) . Flow cytometry data indicate no increase in cell death with cells treated with TGF-b/TNF-a (data not shown).
Of the 12 melanoma cell lines evaluated, cytokine treatment decreased E-cadherin in all the three cell lines in which it was detectable at baseline (DM93, VMM15, and VMM18) (A-C, Fig. 3a ). N-cadherin was increased by cytokine treatment in eight of the 12 melanoma cell lines; however, its expression remained stable in three lines (VMM12, WM115, and SK-MEL-24). In one, VMM5A, N-cadherin expression was undetectable in the untreated cells or in the TGF-b/TNF-a treated cells (Fig. 3b ). Fibronectin expression increased in all melanoma lines except VMM15 (C), whose relative expression level was already 4 pretreatment ( Fig. 3c ). Vimentin expression increased in five lines, stayed the same in four, and interestingly, decreased in three upon TGF-b/TNF-a treatment (Fig. 3d ).
Based on these findings, it appeared that responses to TGF-b/TNF-a treatment in the 12 melanoma cell lines could be grouped into four categories (I-IV) based on a combination of constitutive expression and cytokineinduced changes in E-cadherin and N-cadherin expression ( Fig. 3e ). Category I (three lines) was E-cadherin expression at baseline and had expected results for epithelial cells undergoing EMT, with decreased Ecadherin and increased N-cadherin upon cytokine treatment. The other nine melanoma lines had no detectable E-cadherin protein expression at baseline: five, in category II, had increased N-cadherin with treatment. Three, in category III, had high N-cadherin expression that did not change after cytokine treatment. Just one cell line fell in the last category (IV), where neither E-cadherin nor N-cadherin are expressed in the untreated cells and neither were increased with cytokine treatment.
TNF-a and TGF-b1 cytokine production
In the interest of evaluating whether the melanoma cells themselves may secrete cytokines capable of inducing MT, the production of TNF-a and TGF-b1 by melanoma cells was determined for three melanoma cell lines in three-dimensional culture (one from each category, I-III) before the cytokine treatment to induce MT. In supernatants of cell lines B (VMM18), D (VMM1), and I (VMM12), TGF-b1 was detected at 169, 1188, and 1704 pg/ml, respectively. TNF-a was undetectable in supernatants of all three lines.
E-cadherin, N-cadherin and Snail expression in melanoma tissue
Protein expression by cell lines may or may not reflect insitu expression patterns. We were interested in the expression of E-cadherin and N-cadherin in situ in melanoma, and whether expression of Snail corresponds with N-cadherin expression. Thus, expression of these proteins (E-cadherin, N-cadherin, and Snail) were each assessed by immunohistochemical analysis on a TMA representing 197 melanoma tissue samples, with 3-4 scores each. Ecadherin and N-cadherin were mostly localized to the cell membrane, whereas the Snail staining was nuclear. Proportions of cells staining positive for E-cadherin, Ncadherin and Snail were scored on a scale from 0-4. For Ecadherin, 154 samples (78%) had one or more cores that were positive (score of 1 or more), whereas 128 samples (65%) were positive for N-cadherin. Only eight of 197 samples (4%) had detectable Snail. An example in Fig. 4 is a melanoma sample expressing E-cadherin but negative for N-cadherin and Snail (Fig. 4a-c) . Another core is shown in Fig. 4d -f that is negative for E-cadherin and positive for both N-cadherin and Snail. In Fig. 4g -i is a core that expresses E-cadherin and N-cadherin but is negative for Snail. E-cadherin and N-cadherin staining in Fig. 4g and h are mirror images of each other.
Four staining patterns for E-cadherin and N-cadherin were discerned among the 695 melanoma tissue cores and accounted for 87% of the cores (Fig. 5a ). Thirty-six percent of the cores were N-cadherin negative or low (scores 0-1) but expressed E-cadherin in 51-100% of the cells (scores 3-4); in 23%, E-cadherin was absent or low (0-1), but most melanoma cells expressed N-cadherin (3) (4) . In 17% of the cores, both E-cadherin and Ncadherin were expressed in 51-100% of the cells (3) (4) , whereas in 11%, E-cadherin and N-cadherin was absent or low (0-1). Of the 25 cores positive for Snail (score 1 or higher), the vast majority (21 out of 25, 84%) were also highly positive for N-cadherin (score 3-4) and 15 out of 25 (60%) were negative or low (0-1) for E-cadherin (Fig. 5B) .
The 197 melanoma specimens in the TMA included three that were source tumors for three of the melanoma cell lines used for the MT cultures (VMM15, VMM19, and VMM39). The VMM15 cell line (C) is in group I, expressing E-cadherin and a low level of N-cadherin by western blot, which corresponds well to the corresponding tissue on the TMA, where over 75% of the cells express E-cadherin, N-cadherin is not expressed, and Snail is not detected. Cell lines VMM19 (G) and VMM39 (E) are in group II (E-cadherinand N-cadherin + by western blot). The corresponding melanoma tissue for VMM19 also matches the cell line well, as a low expresser of E-cadherin (score 1) in three of the four cores (the fourth core = score 4) and a high expresser of N-cadherin (expressed in over 75% of the melanoma cells, score 4). The corresponding tissue for cell line VMM39 expresses both E-cadherin and N-cadherin in over 75% of the cells. None of the three tissues expressed Snail.
Discussion
Unlike most epithelial cells, melanocytes and melanoma cells typically express the mesenchymal protein vimentin [26] . A majority of melanoma cells have also lost E-cadherin expression [13, 15, 27] . Baseline protein expression patterns in melanoma cell lines suggest there is a range of 'epithelialness' and 'mesenchymalness' of melanoma cell lines. Surprisingly, there was no direct relationship between the amount of E-cadherin protein expression and expression of any of the mesenchymal proteins or among the mesenchymal proteins in the untreated cells. Thus, there likely is a complex spectrum of epithelial to mesenchymal phenotypes in melanoma before TGF/TNF treatment. In addition, among the proteins we evaluated, there does not appear to be one marker that predicts how melanoma cells will respond to cytokine treatment.
EMT has been shown for some epithelial cells in standard two-dimensional cultures in plastic dishes, however, cell polarization is impaired and growth factors may not be able to access the basolateral side of the monolayer. Three-dimensional culture systems allow the cells to organize into structures that resemble their in-vivo architecture which may promote a more rapid and synchronous EMT (reviewed in [9] ). The three-dimensional culture system we report here represents a more biologically relevant model than monolayer culture in which to examine the effects of cytokine treatment on melanoma cell lines (Mayo, unpublished data).
Melanocytes express E-cadherin [28] . Loss of E-cadherin is a hallmark of EMT. TGF-b can downregulate Ecadherin [29] and the loss of E-cadherin in melanoma can be associated with increased N-cadherin expression [30] . Many of the findings in this study are consistent with an inverse coupling of N-cadherin and E-cadherin expression, with one negatively regulating the other. However, there also are counter examples in which both are absent or both are expressed, suggesting more complex control of their expression. Thus an important area for future study is the molecular and epigenetic control of MT. Although it is theoretically conceivable that the effects of TGF and TNF treatment on cell lines represent selection of more mesenchymal cells, these well established melanoma cell lines are relatively homogeneous and flow cytometry data support that cell death is not increased in the cytokinetreated cells.
Interestingly E-cadherin is undetectable at baseline in nine of the 12 melanoma cell lines analyzed in this study, but they may or may not express mesenchymal proteins; thus, some melanoma cells may have a partially mesenchymal phenotype. In the VMM5 cell line, (category IV) there is no expression of either E-cadherin or N-cadherin, which suggests that the inverse coupling of these two proteins is not absolute. This and other melanomas could possibly include other cadherins such as dysadherin or vascular endothelial-cadherin, which have been associated with aggressive melanoma and indicate a poor prognosis [31, 32] . The expression of dysadherin can downregulate E-cadherin [33] , so it is possible that this or other cadherins are counter-regulated in ways that extend beyond the MT. Multiple cytokines can induce EMT in epithelial cell lines or in epithelial cancers, with variable effects on individual cell lines ( [29, 34] and reviewed in [2, 35] ). TGF-b can induce EMT [29, 36, 37] , whereas other cytokines such as TNF-a can enhance the effects of TGF-b in EMT ( [9] and Mayo, unpublished data). TGFb is found in the melanoma microenvironment [38, 39] and the production of TGF-b is increased in melanoma cells expressing Snail [40] . We measured TGF-b and TNF-a produced by three melanoma cell lines cultured without exogenous cytokines. Group I is thought to be the most 'epithelial-like' whereas group III is thought to be the most 'mesenchymal like'. Data from these three lines are consistent with this subsetting of the melanomas based on 'epithelialness' and 'mesenchymalness,' though a larger study may be necessary to test this association more definitively. We suspected that TGF-b produced by the tumor cells may induce or support MT; so we would expect that TGF-b-producing cell lines would have a more mesenchymal phenotype.
TNF, a mediator of EMT, was not detected in these three cell lines but has been reported to be secreted by a minority of melanoma cells [41] . TNF can be produced by other cells found in the tumor microenvironment including host immune cells. Thus, both TNF-a and TGF-b may be present in the tumor microenvironment and may be able to induce a mesenchymal phenotype spontaneously in vivo. The mesenchymal phenotype has been shown to induce multiple immunosuppressive and immunoresistance mechanisms [40] . This correlation suggests an interesting balance and link among cytokines, EMT, the tumor microenvironment, immune response, tumor invasiveness, and metastatic potential in cancer. It also supports targeting these cytokines and especially TGF-b, in the tumor microenvironment in novel therapies.
Data from the melanoma TMA also support subsetting melanomas based on E-cadherin and N-cadherin expression. Snail was expressed in only 4% of the melanoma tissue samples. We suspect this transcription factor is only transiently expressed during the transition to a more mesenchymal phenotype. In the three cases in which both cell lines and the original tumor were evaluated, there was correspondence of E-and N-cadherin expression, but in another case, there were differences between the tumor and the cell line, which may be explained either by the effects of stromal cells on the tumor in vivo or by selection of a subset of melanoma cells in culture.
A limitation of this study is the semi-quantitative analysis of western blot data for epithelial and mesenchymal protein markers. However, several consistent patterns were observed, especially regarding the presence or absence of epithelial or mesenchymal proteins and regarding changes in protein expression upon TGF-b and TNF-a treatment. In addition, the in-situ studies support the findings that MT can occur in human melanoma, either spontaneously or on exposure to TNF-a and TGFb. Future studies evaluating and understanding the tumor microenvironment, the cytokines that are produced, and their effects on MT may shed further light on the role they play in vivo. If MTof melanoma cells does support invasion and metastasis, as it does in carcinomas, there may be a role in inhibiting the causative factors, either by blocking TGF-b or by inhibiting some downstream signaling from TNF-a within the tumor microenvironment.
